Drug Shortage Report for TEVA-LANSOPRAZOLE
| Report ID | 195649 |
| Drug Identification Number | 02280523 |
| Brand name | TEVA-LANSOPRAZOLE |
| Common or Proper name | TEVA-LANSOPRAZOLE |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | LANSOPRAZOLE |
| Strength(s) | 30MG |
| Dosage form(s) | CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL ORAL |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 500 |
| ATC code | A02BC |
| ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2023-06-19 |
| Estimated end date | Unknown |
| Actual end date | 2025-04-07 |
| Shortage status | Resolved |
| Updated date | 2025-04-25 |
| Company comments | Discontinued |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2023-06-19 | English | Compare |